Cadila Healthcare Latest News

  1. Pursuant to Regulation 39(3) of the SEBI Listing Regulations, Cadila Healthcare has informed that it has received the information of loss of share certificate and request for issue of duplicate share certificate fro...

    Date:27-02-2021
  2. Zydus Cadila has got final approval from USFDA to market Nortriptyline Hydrochloride Capsules
    Date:26-02-2021
  3. Zydus Cadila has received final approval from USFDA to market Nortriptyline Hydrochloride Capsules
    Date:25-02-2021
  4. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
    Date:25-02-2021
  5. Zydus Cadila has received final approval from USFDA to market Droxidopa Capsules
    Date:24-02-2021
  6. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
    Date:19-02-2021
  7. Cadila Healthcare has informed that it has enclosed the Newspaper Publication of Notice of loss of share certificate of the Company, published in the Financial Express.

    Th...

    Date:10-02-2021
  8. Total consolidated income of the company increased by 4.51% at Rs 3,823.10 crore for Q3FY21
    Date:08-02-2021
  9. Total consolidated income of the company increased by 4.51% at Rs 3,823.10 crore for Q3FY21
    Date:06-02-2021
  10. The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis
    Date:05-02-2021
Return to Top
Puchho Befikar